In mid-April, Helicos Biosciences, the first company to market a single-molecule, next generation DNA sequencing platform, announced its financial results for 2009. Yesterday it announced poor Q1 results and restructuring plans. The company faces a precarious future as it burns through its cash reserves and strives to generate new equipment sales. Its auditors have questioned its viability as a going concern. (Read more…)